Supraventricular Tachycardia (AVRT)

1. Comprehensive Executive Overview: Understanding AVRT

Atrioventricular Reentrant Tachycardia (AVRT) is a specific form of paroxysmal supraventricular tachycardia (PSVT) characterized by a rapid heart rate originating above the ventricles. Unlike other forms of SVT that rely on dual pathways within the Atrioventricular (AV) node, AVRT is fundamentally defined by the presence of an accessory pathway (AP)—an extra electrical connection between the atria and the ventricles that bypasses the normal conduction system.

In a healthy heart, the electrical impulse travels from the sinoatrial (SA) node to the AV node, where it is briefly delayed to allow for ventricular filling. In patients with AVRT, the accessory pathway creates a "short circuit," allowing the electrical impulse to travel back and forth between the atria and ventricles in a continuous loop. This reentrant circuit leads to sudden, rapid bursts of tachycardia.

Clinically, AVRT is classified based on the direction of the electrical impulse:
* Orthodromic AVRT: The impulse travels down the AV node and back up the accessory pathway. This is the most common form (approx. 90-95% of cases).
* Antidromic AVRT: The impulse travels down the accessory pathway and back up the AV node. This is rarer and often associated with Wolff-Parkinson-White (WPW) syndrome.

2. Pathophysiology, Etiology, and Risk Factors

The Mechanism of Reentry

The pathophysiology of AVRT relies on the existence of the Bundle of Kent, a congenital anomalous muscular connection. For a reentrant circuit to initiate, there must be a trigger (often a premature atrial contraction) and a disparity in the refractory periods of the AV node and the accessory pathway.

Etiology and Embryology

The accessory pathway is typically a congenital remnant of the developing heart. During embryogenesis, the annulus fibrosus (the insulating tissue between the atria and ventricles) fails to fully isolate the chambers, leaving behind a muscular bridge. While these pathways are present from birth, the tachyarrhythmia may not manifest until adolescence or early adulthood when the physiological properties of the pathways mature.

Risk Factors

3. Signs, Symptoms, and Clinical Presentation

The presentation of AVRT is often paroxysmal, meaning it begins and ends abruptly. Patients frequently describe the sensation as a "racing heart" or "fluttering" in the chest.

Common Symptoms

• Palpitations: The hallmark symptom; often rapid and regular.
• Lightheadedness/Presyncope: Due to reduced cardiac output during the tachycardia.
• Dyspnea: Shortness of breath resulting from increased atrial pressure.
• Chest Pain: Often non-anginal, but caused by the high demand of the rapid heart rate.
• Syncope: Occurs in severe cases where the rapid rate significantly impairs cerebral perfusion.

Physical Examination Findings

During an active episode, the physical exam may reveal a regular, rapid tachycardia (typically 150–250 beats per minute). Patients may exhibit signs of hemodynamic instability, such as hypotension or diaphoresis. In the absence of an episode, the physical exam is often entirely normal, making the history and ECG documentation paramount.

4. Standard Diagnostic Evaluation & Workup

The diagnosis of AVRT requires a systematic approach to confirm the presence of an accessory pathway and distinguish it from other tachyarrhythmias like AVNRT or Atrial Fibrillation.

Electrocardiogram (ECG)

The ECG is the gold standard for initial evaluation.
* During Sinus Rhythm: Look for the "Delta wave"—a slurred upstroke of the QRS complex, which is pathognomonic for WPW syndrome.
* During Tachycardia:
* Orthodromic: Narrow QRS complex, regular rhythm, retrograde P-waves visible after the QRS.
* Antidromic: Wide QRS complex (often mimicking Ventricular Tachycardia), regular rhythm.

Advanced Diagnostics

1. Holter/Event Monitoring: Used for patients with infrequent palpitations to capture the arrhythmia in real-time.
2. Electrophysiology Study (EPS): The definitive diagnostic procedure. An invasive study using catheters to map the electrical activity of the heart, confirm the location of the accessory pathway, and induce the arrhythmia.
3. Echocardiogram: Essential to rule out structural heart disease (e.g., Ebstein’s anomaly, hypertrophic cardiomyopathy).

5. Therapeutic Interventions

Management is divided into acute stabilization and long-term definitive therapy.

Acute Management

For hemodynamically stable patients:
* Vagal Maneuvers: Carotid sinus massage or the Valsalva maneuver to increase vagal tone and terminate the circuit.
* Pharmacotherapy: Adenosine is the first-line agent. It causes a transient AV block, effectively "breaking" the reentrant circuit.
* Calcium Channel Blockers (Diltiazem/Verapamil) or Beta-Blockers: Used for rate control if adenosine is contraindicated.

Note: If the patient is hemodynamically unstable (e.g., severe hypotension, altered mental status), synchronized electrical cardioversion is the immediate treatment of choice.

Long-Term Management

• Catheter Ablation: This is the standard of care and the only curative treatment. Using radiofrequency energy or cryoablation, the electrophysiologist destroys the accessory pathway. The success rate for this procedure is generally >95% with low complication rates.
• Pharmacological Prophylaxis: Reserved for patients who are not candidates for ablation. Anti-arrhythmic drugs (Class IC or III, such as Flecainide or Sotalol) may be used to suppress the arrhythmia.

6. Frequently Asked Questions (FAQ)

1. Is AVRT the same as Wolff-Parkinson-White (WPW) syndrome?
AVRT is the tachycardia that occurs in patients with WPW. WPW refers to the anatomical presence of the accessory pathway (seen on ECG as a delta wave), while AVRT is the actual clinical arrhythmia.

2. Can lifestyle changes cure AVRT?
No. While avoiding triggers like excessive caffeine or stress can reduce the frequency of episodes, lifestyle changes cannot eliminate the accessory pathway. Catheter ablation is the only curative intervention.

3. Is AVRT a life-threatening condition?
In most cases, it is manageable and not life-threatening. However, if the accessory pathway allows for very rapid conduction during atrial fibrillation (pre-excited AF), it can lead to ventricular fibrillation and sudden cardiac arrest.

4. What happens during an ablation procedure?
Ablation is a minimally invasive procedure where catheters are threaded through the veins to the heart. The physician maps the pathway and applies heat or cold to destroy the tissue, effectively "cauterizing" the short circuit.

5. How long does it take to recover from an ablation?
Most patients go home the same day or the following morning. Normal activities can usually be resumed within 2–3 days.

6. Can AVRT come back after surgery?
Recurrence after successful ablation is rare (typically less than 5%). If it does recur, a repeat procedure is usually highly effective.

7. Why does my heart rate increase so suddenly?
The "reentry" mechanism acts like a switch. Once a premature beat hits the circuit at the right time, the electrical impulse begins to loop continuously, causing an instantaneous transition from a normal heart rate to a rapid tachycardia.

8. Are there medications I should avoid if I have AVRT?
Yes. Medications that block the AV node (like Digoxin or certain Beta-blockers) can be dangerous if you have WPW with Atrial Fibrillation, as they may force the electrical impulse to travel down the accessory pathway exclusively, leading to dangerously fast heart rates.

9. Can I exercise with AVRT?
Patients with asymptomatic WPW or controlled AVRT can generally exercise. However, you should consult your cardiologist for a risk-stratification assessment before engaging in competitive athletics.

10. What is the success rate of catheter ablation?
Success rates are extremely high, often exceeding 95-98% in experienced centers, making it the gold standard for long-term management.

Related Clinical Integration

In the management of Atrioventricular Reentrant Tachycardia (AVRT), a comprehensive clinical approach necessitates the integration of continuous hemodynamic surveillance and targeted therapeutic interventions. Patients presenting with symptomatic tachycardia require immediate stabilization and rhythm assessment via a Cardiac Monitor / جهاز مراقبة القلب (معدات طبية عامة) to facilitate real-time diagnostic interpretation. For patients with recurrent or refractory episodes, pharmacological rhythm control may be achieved through the administration of Amiodarone / أميودارون 200mg, while definitive long-term management often involves an Electrophysiology Study (EPS) / دراسة الفيزيولوجيا الكهربائية (EPS) (فحص بالمنظار أو أخذ عينات) to precisely map and ablate the accessory pathways responsible for the reentrant circuit.